Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)

Kodiak Sciences Inc. (NASDAQ:KOD) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 1, 2026, Kodiak Sciences Inc. (NASDAQ:KOD) reported Q4 EPS of ($1.05) compared to (84c) last year. Victor Perlroth, M.D., Chief Executive Officer,  said momentum is building, citing “positive Phase 3 topline results” from the GLOW2 study and progress across late-stage and pipeline programs supporting the company’s long-term strategy.

On March 27, 2026, UBS raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $80 from $50 previously and maintained a Buy rating on the shares. UBS said it is bullish on both tarcocimab VEGF and IL6.

Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)

Photo by José Antonio Otegui Auzmendi on Pexels

Similarly, H.C. Jefferies raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $56 from $39 previously and maintained a Buy rating on the shares, noting GLOW2 results showed improved safety and efficacy versus GLOW1, with the reformulation seen as a safety improvement and potential driver of durability in the Phase III DAYBREAK study, while also supporting earlier Biologics License Application timing.

Kodiak Sciences Inc. (NASDAQ:KOD) develops therapies for retinal diseases.

While we acknowledge the risk and potential of KOD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KOD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.